Coherus BioSciences Ownership
| CHRS Stock | USD 1.18 0.17 12.59% |
Shares in Circulation | First Issued 2013-09-30 | Previous Quarter 114.8 M | Current Value 115.2 M | Avarage Shares Outstanding 64.5 M | Quarterly Volatility 27.6 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Coherus |
Coherus Stock Ownership Analysis
About 70.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.09. Coherus BioSciences last dividend was issued on the June 26, 1995. The entity had 2:1 split on the December 8, 1992. Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. Coherus Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 368 people. For more info on Coherus BioSciences please contact Dennis Lanfear at 650 649 3530 or go to https://www.coherus.com.Besides selling stocks to institutional investors, Coherus BioSciences also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Coherus BioSciences' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Coherus BioSciences' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Coherus BioSciences Quarterly Liabilities And Stockholders Equity |
|
Only 1.36% of Coherus BioSciences are currently held by insiders. Unlike Coherus BioSciences' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Coherus BioSciences' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Coherus BioSciences' insider trades
Coherus Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Coherus BioSciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Coherus BioSciences backward and forwards among themselves. Coherus BioSciences' institutional investor refers to the entity that pools money to purchase Coherus BioSciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Cam Group Holding A/s | 2024-09-30 | 1.9 M | Aqr Capital Management Llc | 2024-09-30 | 1.5 M | Charles Schwab Investment Management Inc | 2024-09-30 | 964.3 K | Tejara Capital Ltd | 2024-09-30 | 958.4 K | Los Angeles Capital Management Llc | 2024-09-30 | 930.1 K | Macquarie Group Ltd | 2024-09-30 | 900 K | Northern Trust Corp | 2024-09-30 | 896.7 K | Lazard Asset Management Llc | 2024-09-30 | 883.7 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 827 K | Blackrock Inc | 2024-09-30 | 12 M | Vanguard Group Inc | 2024-09-30 | 11.3 M |
Coherus BioSciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Coherus BioSciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Coherus BioSciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Coherus BioSciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Coherus BioSciences Outstanding Bonds
Coherus BioSciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Coherus BioSciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Coherus bonds can be classified according to their maturity, which is the date when Coherus BioSciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| CCOI 7 15 JUN 27 Corp BondUS19240CAE30 | View | |
| US19240CAC73 Corp BondUS19240CAC73 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Coherus Stock Analysis
When running Coherus BioSciences' price analysis, check to measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.